Progressive disease and radiographic progression
The point at which a cancer is judged to be growing again despite treatment, usually a 20% increase on scans or a new lesion (RECIST). It ends progression-free survival, usually triggers a change of treatment, and defines 'lines' of therapy.
Progression is assessed on scheduled scans (every 6-12 weeks in trials), so recorded progression dates depend on imaging frequency; blinded central review reduces investigator bias. Immunotherapy introduced pseudoprogression (apparent growth from immune infiltration before shrinkage), handled by iRECIST's 'unconfirmed progression' category, and hyperprogression (rapid acceleration in a minority). Molecular progression (rising ctDNA or PSA) precedes radiographic progression by months and is now used to trigger treatment switches in trials (SERENA-6). Oligoprogression, growth at one or a few sites while the rest is controlled, is treated with local therapy while continuing the systemic drug.
Pages like this
not linked directly; found by shared links- IdeaMake clonal clearance, not tumour shrinkage, a trial endpoint
Shares RECIST, Circulating tumour DNA (ctDNA), Progression-free survival (PFS).
- TermDuration of response (DoR) and disease control rate (DCR)
Shares Complete response (CR) and partial response (PR), Progression-free survival (PFS).
- IdeaA regulatory endpoint for drugs that block spread, not tumours
Shares RECIST, Oligometastatic disease.
- IdeaValidate real-world progression against central imaging review
Shares RECIST, Progression-free survival (PFS).
- IdeaKill combination arms early using circulating tumour DNA, before waiting for scans
Shares RECIST, Circulating tumour DNA (ctDNA), Progression-free survival (PFS).
- IdeaBiopsy the one lesion that is growing while the others shrink
Shares RECIST, Oligometastatic disease.
- IdeaUse a blood test at six weeks to decide whether to keep going
Shares RECIST, Circulating tumour DNA (ctDNA), Progression-free survival (PFS).
- IdeaValidate real-world progression endpoints so pragmatic trials can use them
Shares RECIST, Progression-free survival (PFS).